Engineered immune cells take aim at stubborn KRAS G12D cancers
NCT ID NCT03745326
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This early-phase trial tested a new approach for people with advanced gastrointestinal cancers (like pancreatic, colon, or stomach cancer) that have a specific genetic change called KRAS G12D. Researchers took participants' own white blood cells, genetically modified them in the lab to recognize and attack cancer cells, and then infused them back. The study was small (5 participants) and was terminated early, so we have limited information on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified immune cells (anti-KRAS G12D murine T-cell receptor cells)
What this could lead to
If it works, this could point toward a new treatment for certain hard-to-treat cancers that have a specific KRAS mutation.
What could go wrong
This was a very early, small study (only 5 participants) that was terminated, so results are limited. The treatment involves strong chemotherapy and carries risks of serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.